|
Marker
|
Values
|
Coef
|
SE
|
HR (95% CI)
|
P-value
|
|---|
|
Age at diagnosis
|
Continuous (yrs)
|
0.021
|
0.023
|
1.02 (0.98–1.07)
|
0.36
|
|
Gender
|
Male
| | |
1 (ref)
| |
| |
Female
|
0.109
|
0.272
|
1.11 (0.65–1.90)
|
0.69
|
|
TNM stagea
|
I
| | |
1 (ref)
| |
| |
II
|
0.569
|
0.638
|
1.77 (0.51–6.17)
|
0.37
|
| |
III
|
1.207
|
0.685
|
3.34 (0.87–12.79)
|
0.08
|
| |
IV
|
1.884
|
0.915
|
6.58 (1.09–39.57)
|
0.04
|
|
Fuhrman grade
|
G1
| | |
1 (ref)
| |
| |
G2
|
-0.112
|
0.426
|
0.89 (0.39–2.06)
|
0.79
|
| |
G3
|
-0.047
|
0.437
|
0.95 (0.41–2.25)
|
0.92
|
| |
G4
|
0.955
|
0.462
|
2.60 (1.05–6.43)
|
0.04
|
|
Tumor size
|
Continuous (mm)
|
-0.003
|
0.005
|
1.00 (0.99–1.01)
|
0.59
|
|
NEFH-ii
|
U
| | |
1 (ref)
| |
| |
M
|
-0.002
|
0.298
|
1.00 (0.56–1.79)
|
0.99
|
|
NEURL-ii
|
U
| | |
1 (ref)
| |
| |
M
|
0.475
|
0.280
|
1.61 (0.93–2.78)
|
0.09
|
|
LAD1-ii
|
U
| | |
1 (ref)
| |
| |
M
|
0.738
|
0.258
|
2.07 (1.25–3.43)
|
0.01
|
|
GREM1-ii
|
U
| | |
1 (ref)
| |
| |
M
|
-0.456
|
0.284
|
0.64 (0.36–1.11)
|
0.11
|
|
GATA5
|
U
| | |
1 (ref)
| |
| |
M
|
0.351
|
0.283
|
1.43 (0.82–2.49)
|
0.20
|
- Coef, coefficient; HR, hazard ratio; M, methylated; ref, reference; SE, standard error; TNM, tumor-node-metastasis; U, unmethylated; yrs, years; 95% CI, 95% confidence interval
- aTNM stage as defined in 1987
